VERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
Open Access
- 4 May 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Abstract
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion. Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation. Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.Keywords
This publication has 21 references indexed in Scilit:
- Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: Insights from a 6-month real-world studyInternational Journal of Cardiology, 2024
- Clinical Pharmacokinetic and Pharmacodynamic Profile of VericiguatClinical Pharmacokinetics, 2024
- Impact of vericiguat on heart failure with reduced ejection fraction: a reviewGlobal Health Journal, 2023
- Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure EventsJournal of Cardiac Failure, 2022
- The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fractionHeart Failure Reviews, 2021
- Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA ( Vericiguat Global Study in Subjects with HFrEF ) trialEuropean Journal of Heart Failure, 2021
- Vericiguat: First ApprovalDrugs, 2021
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection FractionJAMA, 2020
- Vericiguat in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2020
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015